MarketPulse

FDA warning letter

24 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Kahn Swick & Foti, Llc

ImmunityBio Stock Crashes 21% After FDA Warning on Cancer Drug Marketing

ImmunityBio faces securities fraud lawsuit following FDA warning letter about Anktiva cancer therapy misleading ads. Stock plummeted to $7.42.
IBRXsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Hagens Berman

ImmunityBio Stock Crashes 21% as FDA Warning Triggers $2B Market Wipeout

ImmunityBio ($IBRX) shares plunged 21% after FDA warning over false Anktiva efficacy claims, erasing $2 billion in market value and triggering securities litigation.
IBRXsecurities class actionstock price decline
GlobeNewswire Inc.GlobeNewswire Inc.··Hagens Berman

ImmunityBio Plunges 21% After FDA Warning Over Unsupported Cancer Claims

ImmunityBio shares plunge 21% after FDA warning over unsupported cancer treatment claims, erasing $2 billion in market value and triggering securities litigation.
IBRXsecurities class actionstock price decline
GlobeNewswire Inc.GlobeNewswire Inc.··Robbins Geller Rudman & Dowd Llp

ImmunityBio Faces Class Action Lawsuit Over Anktiva Cancer Claims

Class action lawsuit filed against ImmunityBio for allegedly making false statements about cancer treatment Anktiva. FDA issued warning letter; stock fell 21% after disclosure.
IBRXsecurities fraudclass action lawsuit